Pediatric high grade glioma: A review and update on tumor clinical characteristics and biology

Frontiers in Oncology

Volumn 2 AUG, Issue , 2012, Pages

  Fangusaro, Jason ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

High grade glioma; Pediatric; Review

Indexed keywords

BEVACIZUMAB; DNA; PROTEIN P53; TEMOZOLOMIDE; VASCULOTROPIN;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; GENE MUTATION; GLIOMA; HUMAN; IMAGING; IMMUNOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84876450750     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00105     Document Type: Review

References (98)

1. Abdel-Rahman, S. M., Reed, M. D., Wells, T. G., and Kearns, G. L. (2007). Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls. Clin. Pharmacol. Ther. 81, 483-494.
2. Baldwin, R. T., and Preston-Martin, S. (2004). Epidemiology of brain tumors in childhood-a review. Toxicol. Appl. Pharmacol. 199, 118-131.
3. Barker, F. G. II, Simmons, M. L., Chang, S. M., Prados, M. D., Larson, D. A., Sneed, P. K., Wara, W. M., Berger, M. S., Chen, P., Israel, M. A., and Aldape, K. D. (2001). EGFR overexpression and radiation response in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 51, 410-418.
4. Barrow, J., Adamowicz-Brice, M., Cartmill, M., Macarthur, D., Lowe, J., Robson, K., Brundler, M. A., Walker, D. A., Coyle, B., and Grundy, R. (2011). Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro. Oncol. 13, 212-222.
5. Bax, D. A., Mackay, A., Little, S. E., Carvalho, D., Viana-Pereira, M., Tamber, N., Grigoriadis, A. E., Ashworth, A., Reis, R. M., Ellison, D. W., Al-Sarraj, S., Hargrave, D., and Jones, C. (2010). A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin. Cancer Res. 16, 3368-3377.
6. Bondy, M. L., Scheurer, M. E., Malmer, B., Barnholtz-Sloan, J. S., Davis, F. G., Il'yasova, D., Kruchko, C., Mccarthy, B. J., Rajaraman, P., Schwartzbaum, J. A., Sadetzki, S., Schlehofer, B., Tihan, T., Wiemels, J. L., Wrensch, M., and Buffler, P. A. (2008). Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 113, 1953-1968.
7. Bredel, M., Pollack, I. F., Hamilton, R. L., and James, C. D. (1999). Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin. Cancer Res. 5, 1786-1792.
8. Broniscer, A. (2006). Past, present, and future strategies in the treatment of high-grade glioma in children. Cancer Invest. 24, 77-81.
9. Broniscer, A., Baker, S. J., West, A. N., Fraser, M. M., Proko, E., Kocak, M., Dalton, J., Zambetti, G. P., Ellison, D. W., Kun, L. E., Gajjar, A., Gilbertson, R. J., and Fuller, C. E. (2007). Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J. Clin. Oncol. 25, 682-689.
10. Broniscer, A., and Gajjar, A. (2004). Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9, 197-206.
11. Buckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., and Uhm, J. H. (2007). Central nervous system tumors. Mayo Clin. Proc. 82, 1271-1286.
12. CBTRUS. (2012). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008. Hinsdale, IL: CBTRUS.
13. ClinicalTrials.gov (2005-2010). Vaccine Therapy in Treating Young Patients who are Undergoing Surgery for Malignant Glioma. ClinicalTrials.gov Identifier: NCT00107185.
14. ClinicalTrials.gov (2006-2012). Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors. ClinicalTrials.gov Identifier: NCT00308165.
15. ClinicalTrials.gov (2009-2012a). An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients with Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma. ClinicalTrials.gov Identifier: NCT00880061.
16. ClinicalTrials.gov (2009-2012b). A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors. ClinicalTrials.gov Identifier: NCT00994071.
17. ClinicalTrials.gov (2010-2012a). A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas. ClinicalTrials.gov Identifier: NCT01130077.
18. ClinicalTrials.gov (2010-2012b). Vorinostat, Temozolomide, or Bevacizumab in Combination with Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients with Newly Diagnosed High-Grade Glioma. ClinicalTrials.gov Identifier: NCT01236560.
19. ClinicalTrials.gov (2012). Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients with Newly Diagnosed Diffuse Pontine Gliomas. ClinicalTrials.gov Identifier: NCT01514201.
20. Cohen, K. J., Pollack, I. F., Zhou, T., Buxton, A., Holmes, E. J., Burger, P. C., Brat, D. J., Rosenblum, M. K., Hamilton, R. L., Lavey, R. S., and Heideman, R. L. (2011). Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro. Oncol. 13, 317-323.
21. Donson, A. M., Addo-Yobo, S. O., Handler, M. H., Gore, L., and Foreman, N. K. (2007). MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr. Blood Cancer 48, 403-407.
22. Duffner, P. K., Krischer, J. P., Burger, P. C., Cohen, M. E., Backstrom, J. W., Horowitz, M. E., Sanford, R. A., Friedman, H. S., and Kun, L. E. (1996). Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J. Neurooncol. 28, 245-256.
23. Dufour, C., Grill, J., Lellouch-Tubiana, A., Puget, S., Chastagner, P., Frappaz, D., Doz, F., Pichon, F., Plantaz, D., Gentet, J. C., Raquin, M. A., and Kalifa, C. (2006). High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Eur. J. Cancer 42, 2939-2945.
24. El Andaloussi, A., Han, Y., and Lesniak, M. S. (2006). Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J. Neurosurg. 105, 430-437.
25. El Andaloussi, A., and Lesniak, M. S. (2006). An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro. Oncol. 8, 234-243.
26. Fallai, C., and Olmi, P. (1997). Hyperfractionated and accelerated radiation therapy in central nervous system tumors (malignant gliomas, pediatric tumors, and brain metastases). Radiother. Oncol. 43, 235-246.
27. Fangusaro, J. (2009). Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J. Child Neurol. 24, 1409-1417.
28. Fangusaro, J., and Warren, K. E. (2012). Abstracts from the 15th International Symposium on Pediatric Neuro-Oncology, June 24-27, 2012, Toronto, Ontario, Canada: an internet-based survey evaluating the standard of care in treating children with newly diagnosed high grade glioma. Neuro Oncol. 14(Suppl. 1), i56-i68.
29. Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T., Allison, J. P., Bigner, D. D., and Sampson, J. H. (2007). Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin. Cancer Res. 13, 2158-2167.
30. Finlay, J. L., Boyett, J. M., Yates, A. J., Wisoff, J. H., Milstein, J. M., Geyer, J. R., Bertolone, S. J., McGuire, P., Cherlow, J. M., and Tefft, M. (1995). Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J. Clin. Oncol. 13, 112-123.
31. Finlay, J. L., Dhall, G., Boyett, J. M., Dunkel, I. J., Gardner, S. L., Goldman, S., Yates, A. J., Rosenblum, M. K., Stanley, P., Zimmerman, R. A., Wallace, D., Pollack, I. F., and Packer, R. J. (2008). Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. Pediatr. Blood Cancer 51, 806-811.
32. Finlay, J. L., and Zacharoulis, S. (2005). The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical-and futuristic-perspective. J. Neurooncol. 75, 253-266.
33. Fomchenko, E. I., and Holland, E. C. (2006). Mouse models of brain tumors and their applications in preclinical trials. Clin. Cancer Res. 12, 5288-5297.
34. Geoerger, B., Hargrave, D., Thomas, F., Ndiaye, A., Frappaz, D., Andreiuolo, F., Varlet, P., Aerts, I., Riccardi, R., Jaspan, T., Chatelut, E., Le Deley, M. C., Paoletti, X., Saint-Rose, C., Leblond, P., Morland, B., Gentet, J. C., Meresse, V., and Vassal, G. (2011). Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro. Oncol. 13, 109-118.
35. Geyer, J. R., Finlay, J. L., Boyett, J. M., Wisoff, J., Yates, A., Mao, L., and Packer, R. J. (1995). Survival of infants with malignant astrocytomas. A report from the Childrens Cancer Group. Cancer 75, 1045-1050.
36. Guruangan, S., Dunkel, I. J., Goldman, S., Garvin, J. H., Rosenblum, M., Boyett, J. M., Gardner, S., Merchant, T. E., Gollamudi, S., and Finlay, J. L. (1998). Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J. Clin. Oncol. 16, 2486-2493.
37. Gururangan, S., Chi, S. N., Young Poussaint, T., Onar-Thomas, A., Gilbertson, R. J., Vajapeyam, S., Friedman, H. S., Packer, R. J., Rood, B. N., Boyett, J. M., and Kun, L. E. (2010). Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J. Clin. Oncol. 28, 3069-3075.
38. Hamada, H., Kurimoto, M., Endo, S., Ogiichi, T., Akai, T., and Takaku, A. (1998). Turcot's syndrome presenting with medulloblastoma and familiar adenomatous polyposis: a case report and review of the literature. Acta Neurochir. (Wien) 140, 631-632.
39. Herrington, B., and Kieran, M. W. (2009). Small molecule inhibitors in children with malignant gliomas. Pediatr. Blood Cancer 53, 312-317.
40. Horbinski, C., Kofler, J., Kelly, L. M., Murdoch, G. H., and Nikiforova, M. N. (2009). Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J. Neuropathol. Exp. Neurol. 68, 1319-1325.
41. Horwitz, M. S., Evans, C. F., Klier, F. G., and Oldstone, M. B. (1999). Detailed in vivo analysis of interferon-gamma induced major histocompatibility complex expression in the central nervous system: astrocytes fail to express major histocompatibility complex class I and II molecules. Lab Invest. 79, 235-242.
42. Hou, L. C., Bababeygy, S. R., Sarkissian, V., Fisher, P. G., Vogel, H., Barnes, P., and Huhn, S. L. (2008). Congenital glioblastoma multiforme: case report and review of the literature. Pediatr. Neurosurg. 44, 304-312.
43. Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., Carol, H., Tajbakhsh, M., Reynolds, C. P., Maris, J. M., Courtright, J., Keir, S. T., Friedman, H. S., Stopford, C., Zeidner, J., Wu, J., Liu, T., Billups, C. A., Khan, J., Ansher, S., Zhang, J., and Smith, M. A. (2007). The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer 49, 928-940.
44. Huszthy, P. C., Daphu, I., Niclou, S. P., Stieber, D., Nigro, J. M., Sakariassen, P. O., Miletic, H., Thorsen, F., and Bjerkvig, R. (2012). In vivo models of primary brain tumors: pitfalls and perspectives. Neuro. Oncol. 14, 979-993.
45. Huylebrouck, M., Lv, S., Duerinck, J., Van Binst, A., Salmon, I., De Greve, J., De Witte, O., Luce, S., Michotte, A., D'Haens, J., and Neyns, B. (2012). An observational study of the first experience with bevacizumab for the treatment of patients with recurrent high-grade glioma in two Belgian University Hospitals. J. Oncol. 2012, 801306.
46. Itoh, H., Hirata, K., and Ohsato, K. (1993). Turcot's syndrome and familial adenomatous polyposis associated with brain tumor: review of related literature. Int. J. Colorectal Dis. 8, 87-94.
47. Jones, C., Perryman, L., and Hargrave, D. (2012). Paediatric and adult malignant glioma: close relatives or distant cousins? Nat. Rev. Clin. Oncol. 9, 400-413.
48. Kauffman, R. E. (2000). Clinical trials in children: problems and pitfalls. Paediatr. Drugs 2, 411-418.
49. Khajavi, K., Comair, Y. G., Prayson, R. A., Wyllie, E., Palmer, J., Estes, M. L., and Hahn, J. F. (1995). Childhood ganglioglioma and medically intractable epilepsy. A clinicopathological study of 15 patients and a review of the literature. Pediatr. Neurosurg. 22, 181-188.
50. Kleihues, P, B. P., Rosenblum, M. K., Paulus, W., and Scheithauer, B. W. (2007). Anaplastic Astrocytoma and Glioblastoma. Albany, NY: WHO Press.
51. Kolb, E. A., Gorlick, R., Maris, J. M., Keir, S. T., Morton, C. L., Wu, J., Wozniak, A. W., Smith, M. A., and Houghton, P. J. (2012). Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer 58, 729-735.
52. Labussiere, M., Sanson, M., Idbaih, A., and Delattre, J. Y. (2010). IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist 15, 196-199.
53. Lai, A., Filka, E., Mcgibbon, B., Nghiemphu, P. L., Graham, C., Yong, W. H., Mischel, P., Liau, L. M., Bergsneider, M., Pope, W., Selch, M., and Cloughesy, T. (2008). Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int. J. Radiat. Oncol. Biol. Phys. 71, 1372-1380.
54. Lemort, M., Canizares-Perez, A. C., Van Der Stappen, A., and Kampouridis, S. (2007). Progress in magnetic resonance imaging of brain tumours. Curr. Opin. Oncol. 19, 616-622.
55. Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., and Schlessinger, J. (1985). Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144-147.
56. Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., and Kleihues, P. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97-109.
57. Melean, G., Sestini, R., Ammannati, F., and Papi, L. (2004). Genetic insights into familial tumors of the nervous system. Am. J. Med. Genet. C Semin. Med. Genet. 129C, 74-84.
58. Milano, G. M., Cerri, C., Ferruzzi, V., Capolsini, I., Mastrodicasa, E., Genitori, L., and Aversa, F. (2009). Congenital glioblastoma. Pediatr. Blood Cancer 53, 124-126.
59. Morris, P. G. (2012). Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials? Anticancer Drugs 23, 579-583.
60. Morton, C. L., Maris, J. M., Keir, S. T., Gorlick, R., Kolb, E. A., Billups, C. A., Wu, J., Smith, M. A., and Houghton, P. J. (2012). Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr. Blood Cancer 58, 566-571.
61. Morton, C. L., Papa, R. A., Lock, R. B., and Houghton, P. J. (2007). Preclinical chemotherapeutic tumor models of common childhood cancers: solid tumors, acute lymphoblastic leukemia, and disseminated neuroblastoma. Curr. Protoc. Pharmacol. Chapter 14, Unit 14 18.
62. Narayana, A., Golfinos, J. G., Fischer, I., Raza, S., Kelly, P., Parker, E., Knopp, E. A., Medabalmi, P., Zagzag, D., Eagan, P., and Gruber, M. L. (2008). Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys. 72, 383-389.
63. Narayana, A., Kelly, P., Golfinos, J., Parker, E., Johnson, G., Knopp, E., Zagzag, D., Fischer, I., Raza, S., Medabalmi, P., Eagan, P., and Gruber, M. L. (2009). Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110, 173-180.
64. Neglia, J. P., Robison, L. L., Stovall, M., Liu, Y., Packer, R. J., Hammond, S., Yasui, Y., Kasper, C. E., Mertens, A. C., Donaldson, S. S., Meadows, A. T., and Inskip, P. D. (2006). New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J. Natl. Cancer Inst. 98, 1528-1537.
65. Niclou, S. P., Danzeisen, C., Eikesdal, H. P., Wiig, H., Brons, N. H., Poli, A. M., Svendsen, A., Torsvik, A., Enger, P. O., Terzis, J. A., and Bjerkvig, R. (2008). A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB J. 22, 3120-3128.
66. Nicolaides, T. P., Li, H., Solomon, D. A., Hariono, S., Hashizume, R., Barkovich, K., Baker, S. J., Paugh, B. S., Jones, C., Forshew, T., Hindley, G. F., Hodgson, J. G., Kim, J. S., Rowitch, D. H., Weiss, W. A., Waldman, T. A., and James, C. D. (2011). Targeted therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 17, 7595-7604.
67. Northcott, P. A., Korshunov, A., Pfister, S. M., and Taylor, M. D. (2012). The clinical implications of medulloblastoma subgroups. Nat. Rev. Neurol. 8, 340-351.
68. Okada, H., Lieberman, F. S., Edington, H. D., Witham, T. F., Wargo, M. J., Cai, Q., Elder, E. H., Whiteside, T. L., Schold, S. C. Jr., and Pollack, I. F. (2003). Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J. Neurooncol. 64, 13-20.
69. Okada, H., Lieberman, F. S., Walter, K. A., Lunsford, L. D., Kondziolka, D. S., Bejjani, G. K., Hamilton, R. L., Torres-Trejo, A., Kalinski, P., Cai, Q., Mabold, J. L., Edington, H. D., Butterfield, L. H., Whiteside, T. L., Potter, D. M., Schold, S. C. Jr., and Pollack, I. F. (2007). Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J. Transl. Med. 5, 67.
70. Panigrahy, A., and Bluml, S. (2009). Neuroimaging of pediatric brain tumors: from basic to advanced magnetic resonance imaging (MRI). J. Child Neurol. 24, 1343-1365.
71. Paugh, B. S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., Bax, D. A., Coyle, B., Barrow, J., Hargrave, D., Lowe, J., Gajjar, A., Zhao, W., Broniscer, A., Ellison, D. W., Grundy, R. G., and Baker, S. J. (2010). Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 28, 3061-3068.
72. Pollack, I. F., Finkelstein, S. D., Woods, J., Burnham, J., Holmes, E. J., Hamilton, R. L., Yates, A. J., Boyett, J. M., Finlay, J. L., and Sposto, R. (2002). Expression of p53 and prognosis in children with malignant gliomas. N. Engl. J. Med. 346, 420-427.
73. Pollack, I. F., Hamilton, R. L., Sobol, R. W., Burnham, J., Yates, A. J., Holmes, E. J., Zhou, T., and Finlay, J. L. (2006). O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J. Clin. Oncol. 24, 3431-3437.
74. Qu, H. Q., Jacob, K., Fatet, S., Ge, B., Barnett, D., Delattre, O., Faury, D., Montpetit, A., Solomon, L., Hauser, P., Garami, M., Bognar, L., Hansely, Z., Mio, R., Farmer, J. P., Albrecht, S., Polychronakos, C., Hawkins, C., and Jabado, N. (2010). Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro. Oncol. 12, 153-163.
75. Reddy, A. T., and Wellons, J. C. III. (2003). Pediatric high-grade gliomas. Cancer J. 9, 107-112.
76. Reulecke, B. C., Erker, C. G., Fiedler, B. J., Niederstadt, T. U., and Kurlemann, G. (2008). Brain tumors in children: initial symptoms and their influence on the time span between symptom onset and diagnosis. J. Child Neurol. 23, 178-183.
77. Rickert, C. H., Strater, R., Kaatsch, P., Wassmann, H., Jurgens, H., Dockhorn-Dworniczak, B., and Paulus, W. (2001). Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am. J. Pathol. 158, 1525-1532.
78. Rood, B. R., and MacDonald, T. J. (2005). Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. J. Neurooncol. 75, 267-272.
79. Rosenfeld, A., Listernick, R., Charrow, J., and Goldman, S. (2010). Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv. Syst. 26, 663-667.
80. Sanders, R. P., Kocak, M., Burger, P. C., Merchant, T. E., Gajjar, A., and Broniscer, A. (2007). High-grade astrocytoma in very young children. Pediatr. Blood Cancer 49, 888-893.
81. Schiffman, J. D., Hodgson, J. G., Vandenberg, S. R., Flaherty, P., Polley, M. Y., Yu, M., Fisher, P. G., Rowitch, D. H., Ford, J. M., Berger, M. S., Ji, H., Gutmann, D. H., and James, C. D. (2010). Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 70, 512-519.
82. Schwartzentruber, J., Korshunov, A., Liu, X. Y., Jones, D. T., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D. A., Tonjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jager, N., Rausch, T., Ryzhova, M., Korbel, J. O., Hielscher, T., Hauser, P., Garami, M., Klekner, A., Bognar, L., Ebinger, M., Schuhmann, M. U., Scheurlen, W., Pekrun, A., Fruhwald, M. C., Roggendorf, W., Kramm, C., Durken, M., Atkinson, J., Lepage, P., Montpetit, A., Zakrzewska, M., Zakrzewski, K., Liberski, P. P., Dong, Z., Siegel, P., Kulozik, A. E., Zapatka, M., Guha, A., Malkin, D., Felsberg, J., Reifenberger, G., Von Deimling, A., Ichimura, K., Collins, V. P., Witt, H., Milde, T., Witt, O., Zhang, C., Castelo-Branco, P., Lichter, P., Faury, D., Tabori, U., Plass, C., Majewski, J., Pfister, S. M., and Jabado, N. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231.
83. Seker, A., and Ozek, M. M. (2006). Congenital glioblastoma multiforme. Case report and review of the literature. J. Neurosurg. 105, 473-479.
84. Sposto, R., Ertel, I. J., Jenkin, R. D., Boesel, C. P., Venes, J. L., Ortega, J. A., Evans, A. E., Wara, W., and Hammond, D. (1989). The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J. Neurooncol. 7, 165-177.
85. Stupp, R., Mason, W. P., Van Den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., and Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996.
86. Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., Ellison, D. W., Lichter, P., Gilbertson, R. J., Pomeroy, S. L., Kool, M., and Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123, 465-472.
87. van Vuurden, D. G., Hulleman, E., Meijer, O. L., Wedekind, L. E., Kool, M., Witt, H., Vandertop, P. W., Wurdinger, T., Noske, D. P., Kaspers, G. J., and Cloos, J. (2011). PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2, 984-996.
88. Varley, J. M. (2003). Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat. 21, 313-320.
89. Walter, A. W., Hancock, M. L., Pui, C. H., Hudson, M. M., Ochs, J. S., Rivera, G. K., Pratt, C. B., Boyett, J. M., and Kun, L. E. (1998). Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J. Clin. Oncol. 16, 3761-3767.
90. Ward, B. A., and Gutmann, D. H. (2005). Neurofibromatosis 1: from lab bench to clinic. Pediatr. Neurol. 32, 221-228.
91. Warren, K. E. (2008). "Pediatric high-grade glioma," in 2008 Education Book. Alexandria, VA: American Society of Clinical Oncology.
92. Warren, K. E., Gururangan, S., Geyer, J. R., Mclendon, R. E., Poussaint, T. Y., Wallace, D., Balis, F. M., Berg, S. L., Packer, R. J., Goldman, S., Minturn, J. E., Pollack, I. F., Boyett, J. M., and Kun, L. E. (2012). A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J. Neurooncol. 106, 643-649.
93. Weissman, Z., Michowitz, S., Shuper, A., Kornreich, L., and Amir, J. (1996). Dysembryoplastic neuroepithelial tumor: a curable cause of seizures. Pediatr. Hematol. Oncol. 13, 463-468.
94. White, E., Bienemann, A., Pugh, J., Castrique, E., Wyatt, M., Taylor, H., Cox, A., Mcleod, C., and Gill, S. (2012a). An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma. J. Neurooncol. 108, 77-88.
95. White, E., Bienemann, A., Taylor, H., Hopkins, K., Cameron, A., and Gill, S. (2012b). A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme. Contemp. Clin. Trials 33, 320-331.
96. Whiteford, C. C., Bilke, S., Greer, B. T., Chen, Q., Braunschweig, T. A., Cenacchi, N., Wei, J. S., Smith, M. A., Houghton, P., Morton, C., Reynolds, C. P., Lock, R., Gorlick, R., Khanna, C., Thiele, C. J., Takikita, M., Catchpoole, D., Hewitt, S. M., and Khan, J. (2007). Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 67, 32-40.
97. Wolff, B., Ng, A., Roth, D., Parthey, K., Warmuth-Metz, M., Eyrich, M., Kordes, U., Kortmann, R., Pietsch, T., Kramm, C., and Wolff, J. E. (2012). Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database. J. Neurooncol. 107, 139-146.
98. Wong, K. K., Tsang, Y. T., Chang, Y. M., Su, J., Di Francesco, A. M., Meco, D., Riccardi, R., Perlaky, L., Dauser, R. C., Adesina, A., Bhattacharjee, M., Chintagumpala, M., and Lau, C. C. (2006). Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res. 66, 11172-11178.